Abstract |
In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.
|
Authors | A Krarup-Hansen, E Andersen, K Elbaek, S N Rasmussen, M Dalmark |
Journal | Acta oncologica (Stockholm, Sweden)
(Acta Oncol)
Vol. 27
Issue 5
Pg. 521-5
( 1988)
ISSN: 0284-186X [Print] England |
PMID | 3203009
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Administration, Oral
- Adult
- Aged
- Drug Evaluation
- Female
- Humans
- Idarubicin
(administration & dosage, adverse effects, pharmacokinetics)
- Male
- Middle Aged
- Neoplasms
(drug therapy)
|